ADHD Medications Show Early Signal for Perimenopause-Related Brain Fog
Two medications used for attention-deficit hyperactivity disorder may offer an unexpected route for treating one of perimenopause’s most frustrating complaints: brain fog. In a review presented at The Menopause Society’s 2026 Annual Meeting, lisdexamfetamine and atomoxetine were linked to better self-reported executive function in midlife women, including improvements in working memory and flexible thinking.
The findings land in an area of medicine where patients have long described a real but difficult-to-measure problem. Forgetfulness, slowed thinking, and trouble organizing daily tasks often emerge during the menopausal transition, yet the available treatments remain limited. Hormone therapy, lifestyle changes, sleep support, and psychological interventions are commonly used, but no medication is approved specifically for menopausal cognitive symptoms.
The clinical question is not whether women feel impaired. They do.
What the Review Examined
Investigators analyzed data from prior studies of lisdexamfetamine and atomoxetine in relation to cognition and ADHD symptom severity. The focus was on cisgender women between 45 and 60 years old whose last menstrual period was less than 10 years earlier. That population matters because it overlaps with the window in which estrogen levels fluctuate sharply and menopausal symptoms often intensify.
The review grew out of earlier work examining the effects of estrogen on ADHD medications, along with clinical observations that many women in midlife describe symptoms resembling ADHD. Jennifer Tat, the lead author and a medical student at the University of Tennessee Health Science Center, framed the work around two linked questions: whether ADHD medications might help menopausal brain fog, and whether women with more ADHD symptoms experience a harder menopausal transition.
Self-Reported Executive Function Improved in Both Drug Arms
Both lisdexamfetamine and atomoxetine improved participants’ self-reported executive function compared with placebo. The gains were most apparent in working memory, a domain that often determines whether a person can keep track of tasks, hold information in mind, and move through a workday without constant mental resets.
For patients, that distinction is practical at the bedside. A woman may not describe her problem as a memory disorder at all; she may say she is losing her train of thought in meetings, forgetting why she walked into a room, or falling behind on routine responsibilities that once felt automatic. Those subjective failures can carry real consequences for job performance, confidence, and emotional well-being even when they do not show up cleanly on standard testing.
Tat said the results support the idea that these symptoms can respond to treatment. The drugs also fit a plausible neurochemical model: both increase dopamine and norepinephrine signaling in the prefrontal cortex, the region most responsible for focus, planning, and working memory. Estrogen loss during perimenopause may weaken those same pathways, creating a biologic rationale for why medications developed for ADHD could help some women with menopausal brain fog.
Objective Cognitive Tests Did Not Move in Parallel
The more sobering finding was the gap between how women felt and what formal testing measured. Despite the improvement in self-reported symptoms, the ADHD medications had little to no significant effect on objective cognitive tests, including measures of working memory and prolonged attention.
That mismatch raises an immediate methodological question about how menopausal brain fog should be measured in the first place. Standard laboratory tests may miss the kinds of day-to-day failures women notice most, while self-report scales may capture lived impairment more accurately but still reflect perception rather than a directly measurable cognitive change. The review does not resolve that tension.
The sample may also have been too small to detect modest improvements. Without larger studies, a modest but clinically meaningful signal can disappear into statistical noise. The absence of measurable change on formal testing should not be taken as proof that the treatment has no effect; it does, however, prevent any claim that these medications restore cognition in a broad or durable way.
Why the Findings Matter for Midlife Women
Kanchi Chadha, an OB/GYN and director of the Midlife Women’s Health and Longevity Center at Hackensack University Medical Center, described the findings as cautiously encouraging. She said nearly 60% of her perimenopausal patients raise concerns about forgetfulness and difficulty concentrating. Her comments reflect a broader clinical reality: menopausal brain fog often emerges during years when many women are managing peak career and caregiving demands.
Chadha also pointed to a treatment gap. Menopause hormone therapy is not recommended for cognition, and not every patient is a candidate for it. Safe, non-hormonal options remain badly needed, especially for women who cannot or do not want to use hormone therapy.
The review also suggests a useful clinical screen. If menopausal symptoms resemble ADHD, then clinicians may need to ask whether some women have longstanding attention symptoms that become more visible during the menopause transition. In that setting, a medication already familiar to psychiatry could potentially have a role, though only after stronger evidence is available.
The Next Trial Needs Better Answers
This review does not justify routine prescribing for menopausal brain fog. It does, however, identify a plausible therapeutic path and a major evidence gap. Larger randomized trials are needed to determine long-term safety, durability of benefit, and whether the effect is limited to women with overlapping ADHD symptoms.
Future studies should also include methylphenidate, compare ADHD medications directly with hormone therapy where appropriate, and recruit more diverse midlife populations. The most important unanswered question is whether the subjective relief women report can be matched by objective improvement in cognition and function over time.
Until those data arrive, the signal remains early and incomplete, not practice-changing.